A Retrospective Assessment of OviTex PRS (OviTex)
← catalyst calendarNCT05736848 · readout in 11 d
Sponsored by Tela Bio Inc (industry) · TELA — their whole pipeline →. With MCRA.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
200estimated
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-27 | actual | When the study began enrolling |
| Primary completion | 2026-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Reconstructive Surgical Procedures
Intervention
- Device: OviTex® PRS — also filed as OviTex PRS Permanent - Pre-pectoral, OviTex PRS Permanent - Sub-pectoral, OviTex PRS Resorbable - Pre-pectoral, OviTex PRS Resorbable - Sub-pectoral
Primary outcome
what the primary-completion date above is the date OFThe occurrence of relevant (S)AEs within 24 months of OviTex® PRS implantation.
measured 24 months
Permalink · TELA's whole pipeline · Catalyst calendar · Every registered study · What changed